Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Feb 15, 2021 3:47pm
193 Views
Post# 32569297

RE:RE:RE:RE:RE:RE:RE:100$ stock price

RE:RE:RE:RE:RE:RE:RE:100$ stock price
crow27 wrote: Thanks Mugs,

People are always concerned of how many AH shares there are but that is irrelevent to ATE shareholders That AH share count is only important to the owners of AH when they split the proceeds of a sale. They could of actually had it in a percentage instead of a share count.
Means nothing to us. What is the most important is the dollar value they are asking and if it is fair to ask that amout.
We need to combine the 2 companies as that is where the big bucks are. ATE could issue shares or cash on hand or a combination. If it's worth what they say it's worth it no matter what that number is and as long as the market considers it fair then we have no problem in aquiring it as our share price will not miss a beat.
IT HAS TO BE FAIR market value!! I have no idea what that number is?

I don't think people are concerned with the internal ownership of Holdings per se, but more with the dilution to ATE SHs if a consolidation were to be done with the issuance of shares.
 
Holdings is not a publicly traded company.  It has an address in Cochrane Alta, but I suspect that is just a mailbox.  I don't think it has any permanent staff. Maybe an accountant and lawyer on retainer to handle arisings. When I tried to look up a phone number a while back, I got Antibe's head office number in Toronto.  I think it owns about 5% of Antibe.
 
If a consolidation were to be done by way of dilution only instead of cash (either upfront or from future milestones), then Wallace and LeGault would definitely gain as AH owners. But they would lose twice by dilution through their direct ownership in ATE and their proportional ownership of AH's 5%.
 
I think they both would prefer cash over shares, for many reasons, and might be amenable to a lower price if some or all of the deal were paid in cash.
 
And as someone previously commented, a consoldidation is only necessarily required in the case of a sale.  So no rush here.

<< Previous
Bullboard Posts
Next >>